Targeting inflammation in non-small cell lung cancer through drug repurposing
Lung cancer is the most common cause of cancer-related deaths. Lung cancers can be classified as small-cell (SCLC) or non-small cell (NSCLC). About 84% of all lung cancers are NSCLC and about 16% are SCLC. For the past few years, there have been a lot of new advances in the management of NSCLC in te...
Saved in:
Main Authors: | Rajasegaran, Thiviyadarshini, How, Chee Wun, Saud, Anoosha, Ali, Azhar, Lim, Jonathan Chee Woei |
---|---|
Format: | Article |
Published: |
Multidisciplinary Digital Publishing Institute
2023
|
Online Access: | http://psasir.upm.edu.my/id/eprint/109107/ https://www.mdpi.com/1424-8247/16/3/451 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Drug repurposing of clinically-approved drugs to target epithelial-mesenchymal transition using in silico analysis
by: Ong, Chun Hao
Published: (2021) -
Drug repurposing of clinically approved drugs to target epithelial-mesenchymal transition using molecular docking approach
by: Chun Hao, Ong, et al.
Published: (2023) -
Lipid nanoparticles in anti-breast cancer drug delivery systems and drug-membrane interactions
by: How, Chee Wun
Published: (2014) -
Nano-mediated strategy for targeting and treatment of non-small cell lung cancer (NSCLC)
by: Ashique, Sumel, et al.
Published: (2023) -
The art of repurposing
Published: (2024)